A maintenance regimen comprising olaparib and bevacizumab led to greater progression-free survival (PFS) in patients newly diagnosed with advanced ovarian cancer, results of the phase III PAOLA-1/ENGOT-ov25* study showed.
Men with metastatic castration-resistant prostate cancer (mCRPC) derived significantly greater clinical benefit from cabazitaxel vs the androgen receptor-targeted agents (ARTA) abiraterone or enzalutamide, according to the results of the CARD* trial presented at ESMO 2019.
Final overall survival (OS) results from the double-blind phase III FLAURA study reinforce osimertinib as the standard frontline treatment for epidermal growth factor receptor-mutated (EGFRm) non–small cell lung cancer (NSCLC), say leading oncologists at ESMO 2019.
Nivolumab, used in the first-line treatment of patients with advanced hepatocellular carcinoma (HCC), has demonstrated clinically meaningful improvements in overall survival (OS) and response rates vs sorafenib in the phase III CheckMate 459 study, although the improvement in OS did not reach statistical significance.
The addition of upfront docetaxel chemotherapy to androgen deprivation therapy (ADT) confers durable and clinically significant benefit in men with hormone-naïve metastatic prostate cancer (mHNPC) regardless of metastatic burden, according to a long-term follow-up of the phase III STAMPEDE* trial reported at ESMO 2019.
Immunotherapy with pembrolizumab appears to increase response rates compared with single-agent chemotherapy in malignant pleural mesothelioma (MPM) patients who have failed a previous line of platinum-based chemotherapy, but this improved response does not translate to survival advantage, according to the results of the phase III PROMISE-meso trial presented at the 2019 Congress of the European Society for Medical Oncology (ESMO).
Systemic treatment tailored by molecular gene expression analysis has failed to improve outcomes of patients with carcinoma of unknown primary origin (CUP), according to the results of the GEFCAPI 04 trial presented at the 2019 Congress of the European Society for Medical Oncology (ESMO 2019).
There appears to be no pressing need for men with prostate cancer to undergo radiotherapy immediately after surgery, according to a recent study presented at the 2019 Congress of the European Society of Medical Oncology (ESMO 2019).
Blood-first next-generation sequencing leads to identification of ALK fusions in patients with nonsmall cell lung cancer, which in turn guides treatment decision-making, according to the initial results of the phase II/III B-FAST* trial presented at the European Society for Medical Oncology (ESMO) Congress 2019.
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.